Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis
International Journal of Cancer, 06/16/09
Zarogoulidis K et al. - In a study to examine the clinical impact of zoledronic acid (ZOL) with a focus on the survival, time to progression, and pain effect in lung cancer pts with bone metastases, it was concluded that the addition of ZOL increases overall survival in lung cancer pts with bone metastases. The longer the period of receiving ZOL, the better effect on survival and time to progression.
Methods- Lung cancer pts (n = 144, Stage IV) with evidence of metastasis bone scan were included.
- 87 of 144 experienced bone pain and received ZOL, 4 mg i.v. every 21 days (Group A), whereas the other 57 pts received no ZOL (Group B).
- All pts were treated with a combination chemotherapy that consisted of docetaxel 100 mg/m2 and carboplatin AUC = 6.
- Group A had a statistically significant longer survival when compared to Group B.
- A statistically significant positive correlation was found between number of cycles of therapy with ZOL and total patient survival and time to progression.
- Pain effect of ZOL had no significant difference between the 2 groups of pts.
- Urine N-telopeptide of type I collagen (NTx) levels decreased in pts with NTx ≤29 nM BCE/mM creatinine at baseline after treatment with ZOL.
Related Articles
Lung cancer: a biologically different disease in women?
Women's Health, 10/30/09
Relevance Score: 73%
Oestrogen plus progestin and lung cancer in postmenopausal women (Womens Health Initiative trial): a post-hoc analysis of a randomised controlled trial
The Lancet, 10/12/09
Relevance Score: 72%
Haplotype and Cell Proliferation Analyses of Candidate Lung Cancer Susceptibility Genes on Chromosome 15q24-25.1
Cancer Research, 10/06/09
Relevance Score: 71%
Noninvasive detection of lung cancer by analysis of exhaled breath
BMC Cancer, 10/09/09
Relevance Score: 70%
African American lung cancer patients may have different response to new cancer-fighting drugs
EurekAlert, 10/08/09
Relevance Score: 70%
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Enhanced activity of the CREB co-activator Crtc1 in LKB1 null lung cancer
Oncogene, 12/16/09
The promyelocytic leukemia zinc-finger gene, PLZF, is frequently downregulated in malignant mesothelioma cells and contributes to cell survival
Oncogene, 12/16/09
IMP3 expression is correlated with histologic grade of lung adenocarcinoma
Human Pathology, 12/16/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


